Background: Copeptin, part of the vasopressin precursor, is increasingly used as marker for vasopressin and is claimed to have better ex vivo stability. However, no study has directly compared the ex vivo stability of copeptin and vasopressin. Methods: Blood of ten healthy volunteers was collected in EDTA tubes. Next, we studied the effect of various pre-analytical conditions on measured vasopressin and copeptin levels: centrifugation speed, short-term storage temperature and differences between whole blood and plasma, long-term storage temperature and repeated freezing and thawing. The acceptable change limit (ACL), indicating the maximal percentage change that can be explained by assay variability, was used as cut-off to determine changes in vasopressin and copeptin.
Introduction
In clinical and epidemiological studies copeptin is increasingly used as a marker for vasopressin, an important hormone for water homeostasis [1] . Copeptin, a 39-aminoacid glycopeptide, is part of the vasopressin precursor hormone pre-pro-vasopressin. When this precursor is split, copeptin and vasopressin are produced in equimolar amounts [2] . It has been demonstrated that copeptin levels correlate well with vasopressin levels during physiological changes in plasma osmolality, from water excess to dehydration, and also in pathologic states, for example, in septic shock [3] [4] [5] [6] . Moreover, a promising role for copeptin as a diagnostic marker in the differentiation of vasopressin-driven fluid homeostasis disorders as hyponatremia and polydipsia, and as prognostic marker in cardiovascular, kidney disease and critical illness, for example, pneumonia, has emerged in the literature [7, 8] .
The rising popularity of copeptin as a surrogate marker for vasopressin is due to the laborious assay and presumed limited ex vivo stability of vasopressin in comparison with copeptin [2] . However, a review of the literature reveals that the effects of various relevant preanalytical conditions, such as centrifugation force and several short-and long-term storage conditions, on both vasopressin and especially copeptin have not been investigated (Table 1 ). The available evidence is sometimes contradictory and often outdated, as the method for vasopressin measurement has changed considerably over the past decades and results obtained in the past with the older assays may therefore not be valid [11] . Moreover, no direct comparison of the ex vivo stability of vasopressin and copeptin has been made so far. 
Vasopressin Copeptin
Type of collection tube Plasma In EDTA tubes more stable compared to serum tubes, no significant difference compared to heparin and fluoride tubes [9] In EDTA tubes more stable compared to serum, heparin, and citrate tubes after 14 days, however, no difference initially [3, 10] Centrifugation settings Plasma Associated with platelet count and inversely associated with centrifugation speed [11, 12] This study aimed to investigate the effect of centrifugation speed, various short-term storing conditions pre-and post-centrifugation, long-term freezer storage, and repeated freeze-thaw cycles on both copeptin and vasopressin levels in blood and plasma to provide evidence based instructions for optimal pre-analytical sample handling.
Materials and methods

Study population and design
Ten healthy volunteers were included in this study in December 2015.
The study was performed in accordance with the principles of the Declaration of Helsinki and was exempted from review by the Medical Ethical Committee of the University Medical Center Groningen. All participants gave written informed consent.
Blood sample collection was performed at 08:00 am after overnight fasting. Blood samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes. Collection in such tubes ensures the best stability of vasopressin and copeptin (Table 1) . The tubes were placed on ice immediately after blood collection. Thereafter, several preanalytic sample handling procedures were evaluated.
To study the effect of relative centrifugal force (RCF), three EDTA tubes of every participant were centrifuged for 10 min at 4 °C at 800 g, at 2000 g and at 5000 g, respectively. Immediately after centrifugation, the platelet count, and plasma vasopressin and copeptin levels were determined. In all other experiments, plasma samples were obtained using an RCF of 2000 g for 10 min at 4 °C, which is routine in clinical practice. Second, the effect of short-term storage duration and storage temperature before measurement of vasopressin and copeptin was studied. Whole blood and plasma samples were stored at 25 °C and at 4 °C for 2, 6 and 24 h. Immediately after these storage periods, whole blood samples were centrifuged at 2000 g and together with the plasma samples stored at - 80 °C until measurement of vasopressin and copeptin after 1 week. As a reference, a plasma sample was stored at - 80 °C for 1 week immediately after collection. Third, the effect of long-term storage and freezer temperature on plasma levels of vasopressin and copeptin was evaluated. For each patient, samples were stored at three different temperatures (- 20 °C, - 80 °C, and - 150 °C). These samples were measured after 1 week, 1 month, and 4 months. Finally, the effect of one, two and four freeze-thaw cycles on the plasma concentration of vasopressin and copeptin was studied. During each cycle, a sample was frozen to - 80 °C and thereafter thawed to room temperature. Gradual temperature change, from - 80 °C to room temperature and vice versa, was ensured in all samples by storing samples first at - 20 °C for 2 h before further processing. Samples that were stored at - 150 °C were transferred to - 80 °C for one night prior to thawing.
Laboratory analysis
Vasopressin and copeptin measurements were performed in the clinical chemistry laboratory of the IJsselland Hospital, Capelle aan den IJssel, The Netherlands. Vasopressin was measured with a competitive radioimmunoassay using rabbit anti-vasopressin-antiserum and a radio-iodinated vasopressin [ 125 I] tracer (DRG Diagnostics, Marbug, Germany). Documented cross-reactivity of the used antibody with oxytocin is < 0.1%. Solid phase extraction with acetic acid was performed to separate vasopressin from plasma with use of C18 columns (Waters Chromatography BV, Etten-Leur, The Netherlands), which has been suggested to be superior to ethanol extraction [11] . In our study, a recovery of 91.9 ± 2.5% was found. The detection limit of the vasopressin assay is 0.25 pmol/L. Values below the detection limit were considered equal to 0.25 pmol/L in the analyses.
Copeptin was measured on a semi-automatic Kryptor analyzer (ThermoFisher, Henningsdorf/Berlin, Germany) using a sandwich chemiluminescent immunoassay (ThermoFisher). Two types of antibodies, anti-copeptin sheep and anti-copeptin mouse antibodies with luminescent proteins attached, are added to the blood samples and form complexes with the copeptin molecules. Upon activation with a nitrogen laser, the antibody-copeptin complexes emits an elongated luminescent signal compared to the free antibodies, allowing quantification of the copeptin concentration. The detection limit of the copeptin assay is 0.7 pmol/L. No values below this detection limit were found in this study.
Assay functionality of the vasopressin and copeptin assays was assessed by measuring high and low levels of the analytes in pooled plasma from human subjects in four-fold for five consecutive days according to the global Clinical and Laboratory Standards Institute (CLSI) EP15 protocol. In this way, the intra-assay and total coefficient of variation (CV) were determined. The intra-assay, or within-day CV was calculated by dividing the mean within-day standard deviation (SD within) by the grand mean of all measured values, times 100%. The total CV is derived from the SD of both within-and between day assay variation, which is calculated by using the formula: SD total = √ ((3/4) × SD within × SD within + B) [18] . B denotes the between-day variation, by averaging the differences between day means and the grand mean. The total SD was thereafter also divided by the grand mean, times 100%.
Data analysis
All variables are presented as median and interquartile range (IQR) because of our small sample size and skewed data distribution. For each participant separately, the percentage change in analyte concentration was calculated as Tsc/Tr × 100 with Tr and Tsc representing the reference concentration and concentration of that study condition, respectively. These calculated changes were evaluated for presence of outliers, using Grubbs analysis [19, 20] . Outliers were excluded from analysis (Supplemental Data, Table 1 ) and the mean percentage differences without outliers were compared with the acceptable change limit (ACL). The ACL is the maximal percentage change that can be explained by assay variability, calculated with the following formula: ACL = Z √2 × CVa, with a Z-value of 1.96 thus representing a 95% confidence range [21] . The analytical coefficient of variation (CVa) was obtained by dividing the SD of the data from the assay functionality assessment in the lower range of hormone concentration by the median of the hormone concentrations measured directly after centrifugation at 2000 g. The ACL is considered our primary outcome analysis. Friedman's ANOVA tests were performed as secondary analysis, with a post-hoc analysis of differences using Wilcoxon signed-rank tests, with Bonferroni corrections to correct for multiple testing. Correlations between vasopressin and copeptin concentrations were assessed using Spearman's correlation analysis. p-Values of < 0.05 were considered statistically significant. All analyses were performed using SPSS (IBM Statistics version 22.0) and Graphpad Prism (version 5.0).
Results
Definition of change
The intra-assay CV of vasopressin was determined as 10.8% at 1.2 ± 0.1 pmol/L (low range) and 5.5% at 5.4 ± 0.3 pmol/L (high range). The total CV of vasopressin was 11% and 4.8% for the low and high range, respectively. The intra-assay CV of copeptin was 9.0% at 3.0 ± 0.3 pmol/L (low range) and 2.2% at 28.9 ± 0.6 pmol/L (high range). The total CV of copeptin was 13.1% and 2.2% for the low and high range, respectively. The median vasopressin and copeptin values of samples centrifuged at 2000 g were 1.46 pmol/L and 5.73 pmol/L, respectively ( Table 2 ). For the calculation of the ACL, analytical CVs were estimated at 9.1% for vasopressin and 6.9% for copeptin. This resulted in an ACL of 25% for vasopressin and of 19% for copeptin. A mean percentage changes in hormone concentration during the various pre-analytical sample handling procedures was defined as significant in case this change exceeded these ACL values.
Effect of centrifugation speed
As shown in Table 2 , the plasma platelet count gradually decreased when whole blood was centrifuged at higher RCF (p < 0.001). Plasma vasopressin concentration also decreased significantly at higher centrifugation speed, with respectively 73% and 86% when these whole blood samples were centrifuged at 2000 g and 5000 g compared to 800 g, thus exceeding the ACL. In contrast, plasma copeptin levels did not differ across samples obtained with these three centrifugation speeds (Table 2) . Plasma vasopressin and copeptin levels showed a significant correlation when blood samples were centrifuged at 2000 g and 5000 g (Spearman's r = 0.84; p = 0.002 and r = 0.89; p < 0.001, respectively) but not when blood samples were centrifuged at 800 g (Spearman's r = 0.54; p = 0.11).
Effect of short-term storage
In whole blood stored at 25 °C, an increase in vasopressin concentration of 48% was observed already after 2 h of storage, and increased even further during continued storage at 25 °C. In whole blood stored at 4 °C, vasopressin was more stable, namely up to 6 h (+ 20%). Copeptin concentrations in whole blood were stable at both temperatures for at least 24 h (at 25 °C + 3% and at 4 °C + 1%). In plasma, vasopressin concentration remained stable up to 6 h when stored at 25 °C (+ 6%) and for at least 24 h when stored at 4 °C (- 2%). Again, copeptin concentration remained stable for all short-term storage conditions studied. These data are summarized in Table 3 and in Figure 1 .
Effect of long-term storage
In Table 4 , the effect of pre-measurement storage at - 20 °C, - 80 °C and - 150 °C for 1 week, 1 month and 4 months is shown. Plasma levels measured immediately after blood withdrawal and centrifugation at 2000 g were used as a reference. Plasma vasopressin levels decreased by 26% after 4 months in - 20 °C, exceeding the ACL of 25%. In contrast, vasopressin was stable for the total study duration in samples stored at - 80 °C and - 150 °C. Copeptin was stable during the entire study duration at all three storage temperatures.
Effect of repeated freezing and thawing
Vasopressin was affected by repeated freezing and thawing, as is shown in Figure 2 and Supplemental Data, Table 2 . After four cycles, change in vasopressin concentration exceeded the predefined ACL of 25% with a decrease of 32% (from 1. In contrast, copeptin concentration was not affected by repeated freezing and thawing with only a non-significant 4% increase after four cycles. Large differences in the effect of repeated freezing and thawing on plasma vasopressin levels were observed between study subjects, with both positive as well as negative changes (Supplemental Data, Figure 1 ), indicating that repeated freeze-thawing not only causes a systematic decrease, but also an increase in variability of measured vasopressin concentration. This was not the case for copeptin (Supplemental Data, Figure 1 ).
Discussion
Our study showed that centrifugation speed, short-term storage temperature (pre-as well as post-centrifugation), and repeated freezing and thawing had a considerable effect on vasopressin levels, but not on copeptin concentrations. Long-term storage for 4 months at - 80 °C and - 150 °C did not affect plasma vasopressin nor copeptin levels, but vasopressin concentration decreased significantly when stored at - 20 °C.
Our observation that a decrease in plasma platelet count, induced by higher centrifugation speed, was accompanied by a decrease in plasma vasopressin concentration is in agreement with findings published already 20 years ago [11, 12] . In one of these studies it was demonstrated that platelet-rich plasma (centrifuged at 140 g) and platelet-free plasma (additional centrifuging at 25,000 g) differed considerably regarding vasopressin levels and it was concluded that ~ 90% of circulating vasopressin was bound to platelets via V1 receptor binding [12, 22] . To our knowledge, our study is the first to show that copeptin concentration, in contrast to vasopressin concentration, is not influenced by centrifugation speed, which suggests that copeptin is not platelet-bound. The correlations between vasopressin and copeptin were significant when centrifuged at 2000 g or 5000 g and differed across the various centrifugation speeds, with the strongest correlations being obtained at the highest centrifugation speed. We assume that the variation in measured vasopressin concentration is greater when a lower centrifugation speed is used due to inter-individual differences in platelet count, explaining the lower correlation coefficient. Differences in centrifugation speed may possibly explain the variability of the correlations between vasopressin and Exceeding the acceptable change limit (predefined as 25% for vasopressin and 19% for copeptin). copeptin that have been published in previous studies, ranging from 0.31 to 0.88 [3, 6, 23, 24] . Our results emphasize both the importance of using a uniform centrifugation speed and the need of a clear description of the applied centrifugation speed in studies that measure vasopressin concentration. Specifically, g-force (RCF), as opposed to the rounds per minute (RPM) should be stated, as the RCF is independent of the centrifuge diameter. In addition to centrifugation force, short-term storage temperature and time before processing blood samples affected vasopressin concentration. Vasopressin was found to be less stable in whole blood than in plasma. Also, storage temperature of 25 °C led to less stability of vasopressin in both whole blood and plasma compared to 4 °C. We observed that vasopressin concentration in whole blood increased significantly over time, both at room temperature (25 °C) and 4 °C. This may be explained by the fact that in plasma after centrifugation free vasopressin is measured, not platelet-bound vasopressin, and that vasopressin is released from platelets during storage, leading to an increase in measured concentration. Two previous studies also showed an increase in vasopressin levels when whole blood was stored at 25 °C with greater stability when blood samples were stored at 4 °C [11, 13] . However, in these studies vasopressin in whole blood stored at 4 °C had longer stability than in our study; at least 24 [13] and even up to 48 h [11] compared to 6 h, respectively. These differences may be explained by the lack of power of the statistical tests implemented in these studies, due to an insufficient number of participants. The stability of vasopressin in plasma observed in our study is in line with the literature [9, 12] . Although we did not specifically study the effect of blood sample collection on ice and centrifuge temperature it can be expected, based on our results of short-term storage temperature of whole blood, that vasopressin levels are more stable when samples are collected on ice and centrifuged at 4 °C in comparison to 25 °C, which is in line with the literature [12] . In contrast, copeptin was not affected by storage temperature conditions in our as well as in other studies [3, 14] . These results indicate that for copeptin measurement it is not necessary to collect blood samples on ice or to centrifuge tubes in a chilled environment.
The present study is the first to show that both vasopressin and copeptin are stable in plasma when stored frozen at - 80 °C and - 150 °C for at least 4 months. When stored at - 20 °C, plasma vasopressin remained stable for only 1 month, whereas copeptin was stable for at least 4 months. Our finding with respect to vasopressin stability at - 20 °C is in contrast with findings in a previous study that showed that vasopressin is not stable when stored for 24 h [17] . This study was, however, performed in the 1970s and discrepancies might be a caused by differences in the vasopressin assay that was used, which has improved significantly over the years [11] , or by blood collection in lithium heparin instead of EDTA collection tubes [9] .
We observed that vasopressin was affected by repeated freezing and thawing, whereas no effect on copeptin levels was found up to four freeze-thaw cycles. A trend for a decrease in vasopressin concentration was observed after already one freeze-thaw cycle. Moreover, we found that the extent of the effect of freezing and thawing on the vasopressin concentrations varied across samples that were studied, indicating that repeated freeze-thaw cycles induce beside a systematic decrease also more variability, both of which are undesirable. Literature on the effect of freezing and thawing is scarce. To our knowledge, only one study reported that endogenous vasopressin level did not change after three subsequent freeze-thaw cycles [17] . However, this has only been studied in one sample. Likewise, only one study investigated the effect of freezing and thawing on copeptin levels and found no effect of four freeze-thaw cycles [3] , in agreement with our findings.
We acknowledge that this study has limitations. In this study we only examined stability during a frozen storage up to 4 months. Future studies should address the stability of vasopressin and copeptin stored for longer periods of time. In addition, vasopressin and copeptin levels were measured only once in each specific condition, which may have increased the chance of unjustly accepting the analytes to be (un)stable. However, performing multiple measurements would have required an unfeasible amount of blood samples and volume per individual. By using the ACL to conclude whether changes are relevant, we corrected for potential measurement errors, because when values exceed the ACL this provides 95% certainty that a change in analyte concentration is not due to assay variability. The implementation of the ACL as a measure for stability, as opposed to merely statistical analysis, is a significant strength of this study. Another strength is that our study is the first to compare the effect of several preanalytic sample handling conditions on vasopressin and copeptin within the same study. In addition, this study is an investigator-initiated study and was performed independently of the manufactures of the copeptin and vasopressin assays.
Based on our study results pre-analytical sample handling recommendations can be made. For measurement of vasopressin, blood samples should be collected on ice and centrifuged at 4 °C immediately after collection at preferably 2000 g or higher RCF. Short-term storage of plasma samples is preferred at 4 °C for a maximum time span of 24 h or, if storage for a longer period is inevitable, plasma samples should be stored at - 80 °C. Repeated freeze-thaw cycles should be avoided. For measurement of copeptin, a less stringent pre-analytical sample handling protocol is necessary as copeptin remained stable in all study conditions.
Conclusions
This study provides more insight in the ex vivo stability of vasopressin and copeptin and adds to the knowledge on optimal sample handling in order to perform reliable measurements. In view of our results, we recommend the use of a strict sample handling protocol in measurements of vasopressin, both to improve between study comparison of vasopressin levels so as to ensure within-laboratory consistency. In contrast, a less strict protocol for copeptin is required, making measurement of copeptin as surrogate for vasopressin an attractive alternative.
